Literature DB >> 10585786

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.

J R Wingard1, P Kubilis, L Lee, G Yee, M White, L Walshe, R Bowden, E Anaissie, J Hiemenz, J Lister.   

Abstract

The records of 239 immunosuppressed patients receiving amphotericin B for suspected or proven aspergillosis were reviewed to determine rates of nephrotoxicity, dialysis, and fatality. The mean and median durations of treatment were 20.4 and 15.0 days, respectively. The creatinine level doubled in 53% of patients and exceeded 2.5 mg/dL in 29%; 14.5% underwent dialysis; and 60% died. A multivariate Cox proportional hazards analysis showed that patients whose creatinine level exceeded 2.5 mg/dL (hazard ratio [HR], 42.02; P<.001), allogeneic bone marrow transplantation (BMT) patients (HR, 6.34; P<. 001), and autologous BMT patients (HR, 5.06; P=.024) were at greatest risk for requiring hemodialysis. Use of hemodialysis (HR, 3. 089; P<.001), duration of amphotericin B use (HR, 1.03 per day; P=. 015), and use of nephrotoxic agents (HR, 1.96; P=.017) were associated with greater risk of death, whereas patients undergoing solid organ transplantation were at lowest risk (HR, 0.46; P=.002). These data indicate that elevated creatinine levels during amphotericin B treatment are associated with a substantial risk for hemodialysis and a higher mortality rate, but the risks vary in different patient groups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585786     DOI: 10.1086/313498

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  58 in total

1.  Next-generation biomarkers for detecting kidney toxicity.

Authors:  Joseph V Bonventre; Vishal S Vaidya; Robert Schmouder; Peter Feig; Frank Dieterle
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

2.  Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.

Authors:  Andreas H Groll; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Raul M Alfaro; Christine King; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 3.  Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis.

Authors:  S B Girois; F Chapuis; E Decullier; B G P Revol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-02       Impact factor: 3.267

4.  Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.

Authors:  Jon A Olson; Jill P Adler-Moore; Julie Schwartz; Gerard M Jensen; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 5.  Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis.

Authors:  S B Girois; F Chapuis; E Decullier; B G P Revol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

Review 6.  Newer antifungal agents.

Authors:  Walid Abuhammour; Eyassu Habte-Gaber
Journal:  Indian J Pediatr       Date:  2004-03       Impact factor: 1.967

7.  Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies.

Authors:  Corrado Girmenia; Giuseppe Cimino; Francesca Di Cristofano; Alessandra Micozzi; Giuseppe Gentile; Pietro Martino
Journal:  Support Care Cancer       Date:  2005-03-09       Impact factor: 3.603

Review 8.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

9.  Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.

Authors:  Rama Falk; Jacob Grunwald; Amnon Hoffman; Abraham J Domb; Itzhack Polacheck
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada.

Authors:  Coleman Rotstein; Michel Laverdière; Anne Marciniak; Farzad Ali
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-09       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.